IRF6
Interferon regulatory factor 6
Also known as: IRF6_HUMAN, LPS, OFC6, VWS, VWS1
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- O14896
- Gene
- IRF6
- Ensembl
- ENSG00000117595
- Chromosome
- 1
- Canonical length
- 467 aa
- Protein class
- Cancer-related genes, Disease related genes, Human disease related genes, Predicted intracellular proteins, Transcription factors
- Subcellular location
- Nucleoplasm,Cytosol
OverviewNCBI Gene
This gene encodes a member of the interferon regulatory transcription factor (IRF) family. Family members share a highly-conserved N-terminal helix-turn-helix DNA-binding domain and a less conserved C-terminal protein-binding domain. The encoded protein may be a transcriptional activator. Mutations in this gene can cause van der Woude syndrome and popliteal pterygium syndrome. Mutations in this gene are also associated with non-syndromic orofacial cleft type 6. Alternate splicing results in multiple transcript variants.[provided by RefSeq, May 2011]
Canonical amino-acid sequenceUniProt
467 residues, UniProt reviewed canonical sequence.
>O14896|IRF6
1 MALHPRRVRL KPWLVAQVDS GLYPGLIWLH RDSKRFQIPW KHATRHSPQQ EEENTIFKAW
61 AVETGKYQEG VDDPDPAKWK AQLRCALNKS REFNLMYDGT KEVPMNPVKI YQVCDIPQPQ
121 GSIINPGSTG SAPWDEKDND VDEEDEEDEL DQSQHHVPIQ DTFPFLNING SPMAPASVGN
181 CSVGNCSPEA VWPKTEPLEM EVPQAPIQPF YSSPELWISS LPMTDLDIKF QYRGKEYGQT
241 MTVSNPQGCR LFYGDLGPMP DQEELFGPVS LEQVKFPGPE HITNEKQKLF TSKLLDVMDR
301 GLILEVSGHA IYAIRLCQCK VYWSGPCAPS LVAPNLIERQ KKVKLFCLET FLSDLIAHQK
361 GQIEKQPPFE IYLCFGEEWP DGKPLERKLI LVQVIPVVAR MIYEMFSGDF TRSFDSGSVR
421 LQISTPDIKD NIVAQLKQLY RILQTQESWQ PMQPTPSMQL PPALPPQLocalizationUniProt · AlphaFold · HPA
Whether an antibody against IRF6 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Intracellular
- Secreted
- No
- Transmembrane segments
- 0
- Mean surface accessibility (rSASA)
- 0.43
- Highest tissue expression
- 104 nTPM
Expression across tissuesHPA
Tissue
- skin: 104 nTPM
- esophagus: 87 nTPM
- vagina: 44 nTPM
- epididymis: 44 nTPM
- urinary bladder: 35 nTPM
- salivary gland: 35 nTPM
Single-cell type
- papillary tip epithelial cells: 40 nCPM
- renal collecting duct intercalated cells: 26 nCPM
- distal convoluted tubule cells: 17 nCPM
- renal collecting duct principal cells: 15 nCPM
- renal connecting tubule cells: 14 nCPM
- loop of henle epithelial cells: 8.7 nCPM
Immune cell
- eosinophil: 0.4 nTPM
- gdT-cell: 0.4 nTPM
- MAIT T-cell: 0.3 nTPM
- naive CD4 T-cell: 0.3 nTPM
- intermediate monocyte: 0.2 nTPM
- naive CD8 T-cell: 0.2 nTPM
Brain region
- cerebellum: 20 nTPM
- choroid plexus: 9.6 nTPM
- midbrain: 5 nTPM
- hypothalamus: 3.9 nTPM
- spinal cord: 3.8 nTPM
- medulla oblongata: 3.4 nTPM
DiseaseUniProt · ClinVar · IEDB · PubMed
Four sources answering four different questions about IRF6.
Disease | AllUniProt
Conditions IRF6 is implicated in, by any mechanism.
- Van der Woude syndrome 1 (VWS1) MIM:119300
- Popliteal pterygium syndrome (PPS) MIM:119500
- Non-syndromic orofacial cleft 6 (OFC6) MIM:608864
Disease | GeneticClinVar
131 pathogenic / likely-pathogenic of 388 ClinVar records.
Conditions with pathogenic or likely-pathogenic variants.
- Van der Woude syndrome
- Popliteal pterygium syndrome
- Orofacial cleft 6, susceptibility to
- Van der Woude syndrome 1
- IRF6-related condition
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 0.13
- gnomAD pLI
- 1
- gnomAD missense Z
- 2.74
- DepMap mean gene effect
- -0.05
- DepMap dependency class
- selective
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 7% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
- cell development
- cranial skeletal system development
- immune system process
- keratinocyte differentiation
- keratinocyte proliferation
- limb development
- mammary gland epithelial cell differentiation
- negative regulation of cell population proliferation
- negative regulation of keratinocyte proliferation
- negative regulation of stem cell proliferation
- positive regulation of DNA-templated transcription
- positive regulation of transcription by RNA polymerase II
- regulation of transcription by RNA polymerase II
- roof of mouth development
- stem cell proliferation
Molecular functions
- DNA binding
- DNA-binding transcription activator activity, RNA polymerase II-specific
- DNA-binding transcription factor activity
- DNA-binding transcription factor activity, RNA polymerase II-specific
- RNA polymerase II cis-regulatory region sequence-specific DNA binding
- sequence-specific DNA binding
- sequence-specific double-stranded DNA binding
Cellular components
Protein domainsUniProt · Pfam · InterPro
- Interferon regulatory factor, DNA-binding domain
- SMAD/FHA domain superfamily
- SMAD-like domain superfamily
- Interferon regulatory factor-3
- Interferon regulatory factor, conserved site
- Winged helix-like DNA-binding domain superfamily
- Winged helix DNA-binding domain superfamily
- Interferon regulatory factor transcription factor
- Interferon-regulatory factor 3
KeywordsUniProt
InteractionsUniProt · HPA
Protein binding partners of IRF6 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads IRF6 as an antibody target. Whether an autoantibody or antibody against IRF6 could matter depends on whether native IRF6 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
IRF6 is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.
Annotation status
The present source text does not explicitly label IRF6 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...